Efficacy and Safety of Alirocumab as Add-on Therapy in High–Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies
Jennifer G. Robinson (Lead / Corresponding author), Helen M. Colhoun, Harold E. Bays, Peter H. Jones, Yunling Du, Corinne Hanotin, Stephen Donahue
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Efficacy and Safety of Alirocumab as Add-on Therapy in High–Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies'. Together they form a unique fingerprint.